They said it at DeviceTalks Boston 2023

Medical device industry leaders from Boston Scientific, Abbott, ZimVie, Medtronic, Stryker and more met at DeviceTalks Boston to share lessons learned and their perspectives on industry trends, device design and medtech innovation.

BD Chair, CEO and President Tom Polen (right) at DeviceTalks Boston with DeviceTalks Editorial Director Tom Salemi [Photo by Jeff Pinette for Medical Design & Outsourcing]

Bidding farewell to DeviceTalks Boston 2023, we look back at an exceptional two-day medical device conference teeming with insights from over 100 top industry leaders.

These experts unfolded many complexities of the medtech industry in more than 35 sessions, walking attendees from the medical device product development continuum through the latest medical innovations and strategies to tackle regulatory challenges, prototyping, manufacturing, product launches and more.

Between the high-profile keynote int…

Read more
  • 0

Data supports Biosense Webster RF ablation for treating AFib

The QDOT Micro catheter. [Image from Biosense Webster/Johnson & Johnson MedTech]Johnson & Johnson MedTech’s Biosense Webster today announced data from a study of its QDOT Micro catheter for treating AFib.

JACC: Clinical Electrophysiology published data from the Q-FFICIENCY study evaluating QDOT Micro’s safety and 12-month effectiveness. The study observed use of the catheter in paroxysmal AFib ablation using a combination of high-power and conventional modes. QDOT features a very high-power, short-duration QMODE+ mode and a conventional-power, temperature-controlled QMODE setting.

Irvine, California-based Biosense Webster conducted its prospective, multicenter study across 22 U.S. centers. It evaluated 166 patients with drug-refractory, symptomatic paroxysmal AFib. The study demonstrated that the use of QDOT’s QMODE+ setting, alone or inc combination with QMODE, improved procedural efficiency. It also showed enhanced 12-month effectivenes…

Read more
  • 0

Medtronic and Johnson & Johnson reportedly consider Shockwave acquisition

The Shockwave Intravascular Lithotripsy (IVL) System uses pressure waves to break up calcification restricting blood flow. [Image from Shockwave Medical]Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) are interested in acquiring Shockwave Medical  (Nasdaq:SWAV), according to a report citing an unnamed source.

The financial news website did not say how the source knows the information or why they are not being identified by name.

“We don’t comment on rumors or speculation,” Medtronic spokesperson Erika Winkels said today.

Johnson & Johnson and Shockwave have not yet responded to requests for comment, but we’ll update this post if they do.

Bloomberg last month said that Boston Scientific (NYSE:BSX) was also eying Shockwave. The Bloomberg report cited “people with knowledge of the matter” — who asked not to be named due to the privacy of the talks.

There’s no doubt Shockwave is hot.…
Read more
  • 0

Johnson & Johnson MedTech: ‘Stay tuned’ for Ottava next-gen surgical robot

Martin Buehler.

It’s been about two and a half years since Johnson & Johnson (NYSE:JNJ) unveiled its plans for a next-generation surgical robot.

At the time, the six-armed “Ottava” system generated a lot of buzz. Johnson & Johnson shared details on the surgical robotic platform set to offer unrivaled flexibility and control compared to the rest of the market. It features six arms to provide more control and flexibility in surgery, while those arms will be integrated into the operating table.

The company said its platform has a zero-footprint design to enable patient access, increase space in the operating room and improve workflow.

Over the past 30 months, though, the company remained tight-lipped over developments with the platform. In October 2021, J&J pushed back the platform’s development timeline by about two years due to multiple factors. It initially expected was to begin the verification and validation processes for …

Read more
  • 0

Johnson & Johnson MedTech’s leader is AdvaMed’s new chair

Johnson & Johnson MedTech EVP and Worldwide Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]AdvaMed announced today that it has named Ashley McEvoy, EVP of MedTech at Johnson & Johnson, as its new chair.

The group’s board of directors unanimously elected McEvoy as its chair during its quarterly meeting yesterday. She is the first woman to serve as chair at the major U.S. medical technology trade association, which was founded in 1974. (Pam Bailey, who is board chair at medtech contract manufacturing giant Integer, was AdvaMed’s CEO from 1999 to 2005.)

McEvoy succeeds Abiomed’s former CEO Michael Minogue. She starts a two-year term as board chair at the same time that major medtech companies such as Johnson & Johnson face a host of challenges. Health provider customers in the U.S. and elsewhere are grappling with staffing shortages and operational challenges. There are macroeconomic headwinds, and the Chinese government is seeki…

Read more
  • 0

The biggest cardiology tech stories from ACC.23

Medtronic, Abbott, iRhythm and more presented new data at a major cardiology conference, ACC.23. [Images courtesy of Medtronic, Abbott and iRhythm] Major medtech players presented a range of intriguing studies at a gathering of some of the biggest names in the cardiology tech space.

Some of the hottest topics were covered this past week at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC) in New Orleans.

Ablation, cardiac implants, monitors and imaging technology represented a handful of the technologies on display. Medtronic, Abbott, Boston Scientific, Edwards and more offered new data on their innovative technologies in these areas.

Here are some of the biggest stories that came out of the cardiology conference.

Excitement builds around using pulsed-field ablation to treat AFib

Medtronic, Boston Scientific and Johnson & Johnson MedTech’s Biosense Webster all released new…

Read more
  • 0

J&J’s Ethicon completes first robot-assisted kidney stone removal with Monarch platform

The Monarch platform for robot-assisted urology procedures. [Image courtesy of Johnson & Johnson’s Ethicon]Ethicon, a Johnson & Johnson MedTech company, today announced the first robotic-assisted removal of kidney stones using the Monarch platform.

Auris Health, an Ethicon subsidiary, received FDA clearance for Monarch for endourological procedures in May 2022. The University of California, Irvine’s UCI Health used the Monarch platform for urology to complete the first procedure.

According to a news release, it’s the first successful robotically assisted, electromagnetic-guided percutaneous access and mini-percutaneous nephrolithotomy procedure. Ethicon said its study involves a collaboration with co-investigator Dr. Mihir Desai from the University of Southern California.

“This clinical study is the first in the world to research and demonstrate the potential for improved navigation, access, clearance and control in mini-PCNL proce…

Read more
  • 0

DeviceTalkers assemble for the final Newsmakers of 2022

In this episode, your diligent team of DeviceTalkers assembled to review our Top 10 events, trends and newsmakers of 2022.

Executive Editor Chris Newmarker, Pharma Editor Brian Buntz, Managing Editor Jim Hammerand, Senior Editor Danielle Kirsh and Associate Editor Sean Whooley joined me, DeviceTalks Editorial Director Tom Salemi, for the latest DeviceTalks podcast.

We’ve got some highs — robots, diabetes — and some lows — supply chain, recalls — and a whole lot of interesting things in between. All-in-all, we’re bullish on what’s to come in 2023! And we only mentioned COVID-19 once.

Companies mentioned in our wide-ranging discussion include Abbott, Abiomed, Ambu, Becton Dickinson, Boston Scientific, CMR Surgical, Dexcom, embecta, Intuitive, Johnson & Johnson Medtech, Medtronic, Neuralink, Philips, Senseonics, Stryker, Synchron, Vicarious Surgical, Zimmer Biomet, ZimVie and many more.

You can listen to other DeviceTalks Podcast Network shows at…

Read more
  • 0

The top 10 cardiac device stories of 2022

[Image from Pixabay]From pulsed-field ablation to non-invasive monitoring, this was an exciting year for cardiac device tech.

Here are the top 10 cardiac device stories from MassDevice and its sister sites:

10. Medtronic to pay Acutus $17M following EU MDR submission of left-heart access portfolio

Earlier this year, Acutus agreed to sell its left-heart access portfolio to Medtronic for $50 million.

9. Abbott confirms first implants of its dual-chamber leadless pacemaker system

The company designed its i2i technology to provide beat-by-beat communication between two leadless pacemakers, with one positioned on the right ventricle and the other in the right atrium.

8. Boston Scientific completes $1.75B Baylis Medical acquisition

The deal expanded Boston Scientific’s electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal platforms. It also gained a family of guidewires, sheaths an…

Read more
  • 0

Johnson & Johnson completes $16.6B Abiomed acquisition

Johnson & Johnson (NYSE:JNJ) announced today that it completed its $16.6 billion acquisition of Abiomed (Nasdaq:ABMD).

Abiomed now becomes part of Johnson & Johnson, operating as a standalone business within its MedTech segment.

“We are excited to officially welcome the talented Abiomed team to Johnson & Johnson. Their patient-first philosophy aligns with our credo and our purpose to change the future of health for humanity,” said Joaquin Duato, CEO of Johnson & Johnson. “This acquisition marks another important step on Johnson & Johnson’s path to accelerating growth in our MedTech business and delivering innovative medical technologies to more people around the world.”

Last month, Johnson & Johnson announced its intention to acquire Abiomed for approximately $16.6 billion. Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares.

Johnson & Johnson last week exten…

Read more
  • 0

Johnson & Johnson extends tender offer for Abiomed acquisition

Johnson & Johnson (NYSE:JNJ) announced today that it extended the expiration date of its offer to acquire Abiomed (Nasdaq:ABMD).

Last month, Johnson & Johnson announced its intention to acquire Abiomed for approximately $16.6 billion. Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares.

The deal includes an upfront payment of $380 per share in cash. Abiomed shareholders also receive a non-tradeable contingent value right (CVR). This entitles the holder to receive up to $35 per share in cash upon the achievement of certain commercial and clinical milestones. Both companies boards of directors approved the transaction.

Upon announcing the transaction, Johnson & Johson said it intends to complete it before the end of the first quarter of 2023.

About the extension

Johnson & Johnson’s offer was previously scheduled to expire at 11:59 p.m. ET on Dec. 13, 2022, according …

Read more
  • 0

CMR Surgical and J&J are partnering on surgical robotics

Versius surgical robotics systems [Image courtesy of CMR Surgical]CMR Surgical announced today that Johnson & Johnson MedTech’s Ethicon business will work with CMR to sell its Versius surgical robotics systems in select markets.

The collaboration involves commercial teams from the two companies working together. They’ll focus on selling to select hospitals in Italy, France, Germany and Brazil.

“By entering into this collaboration agreement with Ethicon in select markets, CMR believes that this combination of expertise in minimal access surgery and digital innovation will deliver an optimized offering to customers” CMR Surgical CEO Per Vegard Nerseth said in a news release. “CMR looks forward to progressing this agreement in strategically important regions as CMR continues to rapidly expand on a global scale.”

The news comes only weeks after the Cambridge, U.K.–based surgical robotics upstart announced that it had inst…

Read more
  • 0